FDA to review Gen-Probe test

FDA accepted for review a PMA from Gen-Probe Inc. (NASDAQ:GPRO) for the Progensa PCA3 assay to aid in determining the need for a repeat biopsy in men suspected of having prostate cancer. According the company, the agency said the Medical Devices Advisory Committee's Immunology Panel will meet to discuss the application. A date for the meeting has not yet been set. ...